Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

High periostin expression correlates with aggressiveness in papillary thyroid carcinomas.

Puppin C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G.

J Endocrinol. 2008 May;197(2):401-8. doi: 10.1677/JOE-07-0618.

2.

Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.

Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ 3rd, Zarnegar R.

Ann Surg Oncol. 2012 Mar;19(3):973-80. doi: 10.1245/s10434-011-2029-0. Epub 2011 Aug 31.

PMID:
21879273
3.

Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours.

Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG, Leite V.

Br J Cancer. 2004 Aug 16;91(4):732-8.

4.

Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.

Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ.

Clin Endocrinol (Oxf). 2009 Apr;70(4):629-35. doi: 10.1111/j.1365-2265.2008.03376.x. Epub 2008 Aug 15.

PMID:
18710471
5.

Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis.

Shi Y, Zou M, Farid NR.

Clin Endocrinol (Oxf). 1993 Sep;39(3):269-74.

PMID:
8222289
6.

PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.

Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A.

Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5.

PMID:
24316730
7.

Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.

Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G.

Thyroid. 2009 Mar;19(3):247-55. doi: 10.1089/thy.2008.0235.

PMID:
19207009
8.

Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.

Ulivieri A, Lavra L, Dominici R, Giacomelli L, Brunetti E, Sciacca L, Trovato M, Barresi G, Foukakis T, Jia-Jing L, Larsson C, Bartolazzi A, Sciacchitano S.

J Pathol. 2008 May;215(1):87-96. doi: 10.1002/path.2331.

PMID:
18306168
9.

NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas.

Górka B, Skubis-Zegadło J, Mikula M, Bardadin K, Paliczka E, Czarnocka B.

Br J Cancer. 2007 Aug 20;97(4):531-8. Epub 2007 Jul 31.

10.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

11.

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.

Endocr Relat Cancer. 2006 Jun;13(2):455-64.

12.

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.

Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.

13.

Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.

Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL, Shen J, Gattuso P, Prinz RA.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5968-79.

14.

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R.

Endocr Relat Cancer. 2008 Mar;15(1):191-205. doi: 10.1677/ERC-07-0212.

15.

HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A.

Eur J Cancer. 2008 May;44(7):1015-21. doi: 10.1016/j.ejca.2008.02.039. Epub 2008 Mar 28.

PMID:
18375116
16.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
17.

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A.

Clin Cancer Res. 1998 Feb;4(2):287-94.

18.

BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.

Lee JH, Lee ES, Kim YS, Won NH, Chae YS.

Pathology. 2006 Jun;38(3):201-4.

PMID:
16753739
19.

Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Bruland O, Fluge Ø, Akslen LA, Eiken HG, Lillehaug JR, Varhaug JE, Knappskog PM.

BMC Cancer. 2009 Dec 8;9:425. doi: 10.1186/1471-2407-9-425.

Supplemental Content

Support Center